CTC Bio

CTC Bio FCF Margin

The Free Cash Flow Margin of CTC Bio (060590.KQ) as of Oct 28, 2026 is 2.79 %. In the previous year, Free Cash Flow Margin was 1.63 % — a change of 71.19% (higher).

FCF Margin

2.79 %

YoY

71.19%

Last updated:

Free Cash Flow Margin of CTC Bio is 2025 2.79 % . Free Cash Flow Margin of CTC Bio was 2024 1.63 % . It decreases by 71.19% higher compared to the previous year.

The CTC Bio FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-2.87 KRW
Jan 1, 2019
-0.40 KRW
Jan 1, 2020
-1.09 KRW
Jan 1, 2021
3.41 KRW
Jan 1, 2022
9.11 KRW
Jan 1, 2023
4.59 KRW
Jan 1, 2024
1.63 KRW
Jan 1, 2025
2.79 KRW
The CTC Bio FCF Margin history
YEARFCF MarginYoY
2.79 %+71.19%
1.63 %-64.46%
4.59 %-49.60%
9.11 %+167.25%
3.41 %-413.51%
-1.09 %+174.11%
-0.40 %-86.17%
-2.87 %+3.82%
-2.76 %-48.42%
-5.36 %-71.37%
-18.72 %-19.02%
-23.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CTC Bio Stock analysis

What does CTC Bio do? CTC Bio, Inc. generates revenue through the manufacture and sale of pharmaceuticals, including anticancer agents, antibiotics, bone injury treatments, antiulcer agents, and blood flow stimulants. The company also produces veterinary drugs such as vaccines, antibiotics, immune enhancers, enzymes, organic acid, and avian influenza-related agents, alongside animal feed supplements like pigments, kapok seed meal, and sesame meal. Functional food products, including enzymes and lactobacillus for dairy applications, form another revenue stream. The firm distributes these products domestically and internationally, targeting healthcare providers, veterinarians, and food manufacturers. The company's pharmaceutical segment serves medical professionals seeking treatments for cancer, infections, and gastrointestinal issues. Veterinary drug sales cater to animal health practitioners requiring vaccines and antibiotics for livestock. Animal feed supplements are sold to agricultural businesses, while functional food ingredients target dairy producers. CTC Bio, Inc. leverages its in-house pharmaceutical manufacturing technology and know-how to support product development and maintain competitive pricing. Revenue streams include direct sales of pharmaceuticals, veterinary drugs, animal feed supplements, and functional food ingredients. Domestic markets absorb the majority of these products, with international distribution expanding its reach. The company's focus on integrated production of pharmaceuticals, animal health solutions, and functional food components ensures consistent demand across multiple industry segments. CTC Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CTC Bio stock

Free Cash Flow Margin of CTC Bio is 2.79 % in 2025.

Free Cash Flow Margin of CTC Bio changed from 1.63 % to 2.79 %, representing a 71.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin CTC Bio since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's CTC Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CTC Bio

All Key Metrics — CTC Bio